查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年個人化醫療市場預測：按產品、應用、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383451

到 2030 年個人化醫療市場預測：按產品、應用、最終用戶和地區進行的全球分析

Personalized Medicine Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球個人化醫療市場規模為 3,390 億美元，預計在預測期內將以 13.0% 的年複合成長率成長，到 2030 年達到 7,970 億美元。

個人化醫療在很大程度上依賴藥物基因組學測試。透過確定患者的基因組成如何影響治療反應，醫療專業人員可以為每位患者選擇最安全、最有效的藥物和劑量。透過發現特定的基因突變並開發針對這些問題根源的藥物，個人化醫療正在徹底改變罕見疾病的診斷和治療。

據世界衛生組織 (WHO) 稱，癌症是世界上第一大死亡原因，2018 年估計有 960 萬人死亡。這意味著全世界大約六分之一的人將死於癌症。

標靶治療的興起

個人化醫療領域極大地受益於標靶治療的出現。個人化醫療的一個基本要素是標靶治療，它是專門針對患者疾病的遺傳或分子方面而創建的。將標靶治療治療與標準治療進行比較時，優點之一是減少副作用。此外，與傳統的一刀切治療方法相比，根據患者的遺傳和分子特徵量身定做治療可降低副作用的可能性，並且通常會產生更好的治療結果。透過識別最有可能從此類藥物中受益的患者，個人化醫療增加了成功的可能性。

高成本

高昂的費用可能會成為進入的障礙，而個體化的治療可能會保留給有能力獲得的人。這可能會導致醫療保健方面的不平等，有些人可以獲得個體化的、最最先進治療，而有些人則無法獲得。個體化藥物治療的高昂成本可能會對醫療保健預算造成壓力，並使保險公司和衛生系統難以承保。這可能會限制國家和地方醫療保健系統可以提供的最先進治療的數量。由於個人化醫療價格昂貴，有些患者可能不願意接受個人化醫療，錯過了接受更安全、更成功的個人化醫療，這種情況也有可能發生。

提高藥物開發效率

在高效藥物開發系統的支持下，科學發現和研究成果可以更快轉化為實際治療方法。因此，患者將受益於遺傳學和分子生物學的最新進展，更快更快地接受客製化治療方法。此外，透過更有效的藥物開發有望降低成本。因此，更廣泛的患者可能會受益並獲得個人化藥物，這些藥物變得更加便宜和可用，從而推動市場成長。

可及性有限

如果個人化藥物不能廣泛使用，醫療保健差距可能會加劇。如果個體化治療的患者接受較差或無效的治療，而無法負擔這些服務的患者接受較差或無效的治療，則可能會出現不同的健康結果。成本考量可能會限制患者選擇個體化治療的能力，並減少他們對醫療保健的自主權。獲得個人化醫療的人數減少可能意味著缺乏對該領域的研究和治療結果至關重要的多樣化患者資料。資料不足可能會阻礙新治療方法和診斷的進展。

COVID-19 的影響

醫療保健系統和資源對 COVID-19 大流行的最初反應是為了控制和遏制病毒。非緊急醫療活動的大量資金被挪用，其中包括一些有針對性的醫療計劃。個人化醫療計劃可以受益於大流行期間遠端醫療和遠端監控的顯著增加。遠距醫療使得收集患者資料並將其涵蓋個體化治療方法成為可能，特別是慢性病和心理健康問題的管理，對市場成長有正面影響。

個人化醫療治療領域預計在預測期內規模最大

由於基因組序列測定技術的進步以及遺傳和分子資料獲取的增加，個人化個人化醫療市場正在穩步擴大，因此個人化醫療領域預計將出現良好的成長。隨著分子生物學和遺傳學知識的擴展，這種成長預計將持續下去。遺傳諮詢師越來越積極教育病人遺傳資訊對健康的影響。這是個人化治療的重要組成部分，因為患者做出明智的決定非常重要。

預計醫學領域在預測期內的年複合成長率最高。

預計精神病學領域在預測期內將出現最高的年複合成長率年成長率，因為它對於確定哪些精神藥物最有效以及哪些可能引起副作用非常有用。基因檢測和生物標記研究可以幫助預測患者對某些精神藥物的反應。這使醫療保健專業人員擺脫了確定治療精神疾病典型的適當處方和劑量的試驗（有時是漫長的過程）。糖尿病和心血管疾病等合併症在精神疾病患者中很常見。

比最大的地區

由於雅培、Qiagen、GE Healthcare 和BASF SE 等許多重要公司的存在，預計北美在預測期內將佔據最大的市場佔有率。此外，北美地區糖尿病、心臟病和癌症等慢性病的盛行率不斷增加，推動了對客製化醫療解決方案的需求，以提供更有針對性和更有效的治療。此外，北美擁有高度複雜的醫療保健系統，高度重視創新和最尖端科技的實施。因此，客製化醫療技術正在興起並在該地區廣泛應用。

複合年複合成長率最高的地區：

預計亞太地區在預測期內的年複合成長率最高。這是由於該地區製藥公司的存在以及中國和印度等人口大國購買力的不斷上升推動了市場擴張。此外，由於個體化藥物成本不斷上升，以及使用高科技處理來增強客製化解決方案的創建，預計該市場將會發展。此外，亞太地區人口正在顯著成長，這增加了對更個體化醫療保健（包括個體化藥物）的需求。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球個人化醫療市場：依產品

  • 個人化醫療
    • 藥品
    • 醫療設備
    • 基因組醫學
  • 個人化醫療診斷
    • 深奧實驗室服務
    • 直接面對消費者 (DTC) 診斷
    • 基因檢測
    • 困難的實驗室測試
  • 個體化醫療
    • 健康資訊技術
    • 遠端醫療
  • 個人化營養與健康
    • 補充和替代醫學
    • 零售營養品
  • 其他產品

第6章 全球個人化醫療市場：依應用分類

  • 心臟病學
  • 腫瘤學
  • 抗病毒藥
  • 精神病學
  • 神經病學
  • 免疫學
  • 其他用途

第7章 全球個人化醫療市場：依最終用戶分類

  • 醫院
  • 研究/學術機構
  • 診斷中心
  • 其他最終用戶

第8章 全球個人化醫療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Decode Genetics
  • QIAGEN
  • Precision Biologics
  • Biogen
  • Genelex
  • IBM
  • Genentech, Inc.
  • 23andMe, Inc
  • GE Healthcare
  • Illumina, Inc
  • ASURAGEN
  • Aadi Bioscience, Inc.
  • Takeda Pharmaceutical Company Ltd
  • ARIEL Precision Medicine, Inc.
  • Hoffmann-La Roche Ltd.
  • Abbvie Inc
  • Eli Lilly and Company
Product Code: SMRC24299

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $339 billion in 2023 and is expected to reach $797 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Personalized medicine heavily relies on pharmacogenomic testing. It makes it possible for medical professionals to select the safest and most effective medications and doses for each patient by identifying how a person's genetic composition influences how they respond to treatment. By discovering certain genetic variants and creating medicines that target the underlying causes of these problems, personalized medicine is revolutionizing the diagnosis and treatment of uncommon diseases.

Cancer is the biggest cause of mortality worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018. This means that cancer is responsible for around 1 in every 6 deaths worldwide.

Market Dynamics:

Driver:

Rise in targeted therapies

The discipline of customized medicine has greatly benefited by the advent of targeted medicines. One essential element of personalized medicine is targeted medicines, which are created to explicitly target the genetic or molecular aspects of a patient's illness. Comparing targeted therapies to standard treatments, one benefit is the decrease in adverse effects. Moreover, the probability of side effects is reduced by customizing therapies based on a patient's genetic or molecular profile, comparing targeted therapy to conventional, one-size-fits-all methods; greater treatment outcomes are frequently achieved. By identifying patients who are most likely to benefit from these medicines, personalized medicine increases the likelihood of success.

Restraint:

High cost

Exorbitant expenses may erect obstacles to entry, reserving tailored treatment for those with the means to obtain it. Healthcare inequalities may arise from this, with certain individuals receiving individualized, cutting-edge therapies while others lack access to them. Budgets for healthcare may be strained by the high expenses of individualized medication, which insurers and healthcare systems may find difficult to cover. This may restrict the number of these cutting-edge therapies that are offered by national or local healthcare systems. Because personalized medicine can be expensive, some patients may decide not to seek it and this could lead to missed chances for individualized therapies that might be safer and more successful.

Opportunity:

Drug development efficiency

Scientific discoveries and research findings may be translated into practical therapies more swiftly with the aid of efficient drug development systems. As a result, patients will benefit from customized therapy sooner and more quickly from the most recent advances in genetics and molecular biology. Additionally, the cost reductions may result from more effective medication development. Thus, a wider range of patients may benefit from and be able to acquire customized medications due to their increased affordability and accessibility thereby enhancing the growth of the market.

Threat:

Limited accessibility

Healthcare disparities may worsen if tailored medication is not widely available. There may be differences in health outcomes if patients who can afford individualized therapies receive subpar or ineffective care, while those who cannot afford these services may receive subpar or ineffective care. Cost considerations may prevent patients from selecting individualized therapy, which would reduce their autonomy over their medical care, less people having access to customized medicine might mean a lack of diverse patient data, which is essential for the field's achievements in research and treatment, insufficient data can impede the advancement of novel treatments and diagnostics.

COVID-19 Impact

Healthcare systems' and resources' first response to the COVID-19 pandemic has redirected them toward controlling and containing the virus. Numerous funds, including some targeted medicine projects, were taken away from non-urgent medical operations. Personalized medicine projects can benefit from the huge increase in telemedicine and remote monitoring that occurred during the epidemic. Remote consultations have made it possible to gather patient data and incorporate it into individualized treatment regimens, particularly for the management of chronic illnesses and mental health issues which has positively impacted the market growth.

The personalized medicine therapeutics segment is expected to be the largest during the forecast period

The personalized medicine therapeutics segment is estimated to have a lucrative growth, as this market for customized medicine has been steadily expanding due to developments in genomic sequencing technology and the growing accessibility of genetic and molecular data. It is anticipated that this rise will continue in the upcoming years as our knowledge of molecular biology and genetics expands. Genetic counselors are becoming more and more active in educating patients about the effects of their genetic information on their health. This is a vital part of customized treatment since it is important for patients to make educated decisions.

The psychiatry segment is expected to have the highest CAGR during the forecast period

The psychiatry segment is anticipated to witness the highest CAGR growth during the forecast period, as this can be very helpful in psychiatry when figuring out which psychotropic drugs are most likely to work and which can have negative side effects. Predicting a patient's reaction to particular psychiatric drugs can be aided by genetic testing and biomarker research. This spares medical professionals from the sometimes drawn-out process of trial and error involved in determining the appropriate prescription and dose, which is typical in the treatment of mental illness. Comorbid diseases like diabetes or cardiovascular problems are common in people with mental illnesses.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the existence of many significant companies, including Abbott, Qiagen, GE Healthcare, and BASF SE. Furthermore, the rising rate of chronic illnesses in North America, including diabetes, heart disease, and cancer, is driving up demand for customized medical solutions that offer more focused and efficient therapies. Additionally, North America boasts a very sophisticated healthcare system that places a high value on innovation and the uptake of cutting-edge technologies. This has made it possible for customized medical technologies to emerge and become widely used in the area.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India are responsible for the market's expansion. Additionally, it is projected that the market will develop due to an increase in the cost of personalized medication and the use of high-tech processing to enhance the creation of tailored solutions. Moreover, the Asia-Pacific area has a sizable and expanding population, which is increasing the need for more individualized medical treatments, including individualized medications.

Key players in the market

Some of the key players profiled in the Personalized Medicine Market include: Abbott, Dako A/S, Exact Sciences Corporation, Decode Genetics, QIAGEN, Precision Biologics, Biogen, Genelex, IBM, Genentech, Inc., 23andMe, Inc, GE Healthcare, Illumina, Inc, ASURAGEN, Aadi Bioscience, Inc., Takeda Pharmaceutical Company Ltd, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd., Abbvie Inc and Eli Lilly and Company

Key Developments:

In November 2023, Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

In October 2023, Exact Sciences Corp. announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

  • Personalized Medicine Therapeutics
  • Personalized Medicine Diagnostics
  • Personalized Medical Care
  • Personalized Nutrition & Wellness
  • Other Products

Applications Covered:

  • Cardiology
  • Oncology
  • Antiviral
  • Psychiatry
  • Neurology
  • Immunology
  • Other Applications

End Users Covered:

  • Hospitals
  • Research & Academic Institutes
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Therapeutics
    • 5.2.1 Pharmaceutical
    • 5.2.2 Medical Devices
    • 5.2.3 Genomic Medicine
  • 5.3 Personalized Medicine Diagnostics
    • 5.3.1 Esoteric Lab Services
    • 5.3.2 Direct-To-Consumer (DTC) Diagnostics
    • 5.3.3 Genetic Testing
    • 5.3.4 Esoteric Lab Tests
  • 5.4 Personalized Medical Care
    • 5.4.1 Health Information Technology
    • 5.4.2 Telemedicine
  • 5.5 Personalized Nutrition & Wellness
    • 5.5.1 Complementary & Alternative Medicine
    • 5.5.2 Retail Nutrition
  • 5.6 Other Products

6 Global Personalized Medicine Market, By Application

  • 6.1 Introduction
  • 6.2 Cardiology
  • 6.3 Oncology
  • 6.4 Antiviral
  • 6.5 Psychiatry
  • 6.6 Neurology
  • 6.7 Immunology
  • 6.8 Other Applications

7 Global Personalized Medicine Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Research & Academic Institutes
  • 7.4 Diagnostic Centers
  • 7.5 Other End Users

8 Global Personalized Medicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott
  • 10.2 Dako A/S
  • 10.3 Exact Sciences Corporation
  • 10.4 Decode Genetics
  • 10.5 QIAGEN
  • 10.6 Precision Biologics
  • 10.7 Biogen
  • 10.8 Genelex
  • 10.9 IBM
  • 10.10 Genentech, Inc.
  • 10.11 23andMe, Inc
  • 10.12 GE Healthcare
  • 10.13 Illumina, Inc
  • 10.14 ASURAGEN
  • 10.15 Aadi Bioscience, Inc.
  • 10.16 Takeda Pharmaceutical Company Ltd
  • 10.17 ARIEL Precision Medicine, Inc.
  • 10.18 Hoffmann-La Roche Ltd.
  • 10.19 Abbvie Inc
  • 10.20 Eli Lilly and Company

List of Tables

  • Table 1 Global Personalized Medicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Personalized Medicine Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Personalized Medicine Market Outlook, By Personalized Medicine Therapeutics (2021-2030) ($MN)
  • Table 4 Global Personalized Medicine Market Outlook, By Pharmaceutical (2021-2030) ($MN)
  • Table 5 Global Personalized Medicine Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 6 Global Personalized Medicine Market Outlook, By Genomic Medicine (2021-2030) ($MN)
  • Table 7 Global Personalized Medicine Market Outlook, By Personalized Medicine Diagnostics (2021-2030) ($MN)
  • Table 8 Global Personalized Medicine Market Outlook, By Esoteric Lab Services (2021-2030) ($MN)
  • Table 9 Global Personalized Medicine Market Outlook, By Direct-To-Consumer (DTC) Diagnostics (2021-2030) ($MN)
  • Table 10 Global Personalized Medicine Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 11 Global Personalized Medicine Market Outlook, By Esoteric Lab Tests (2021-2030) ($MN)
  • Table 12 Global Personalized Medicine Market Outlook, By Personalized Medical Care (2021-2030) ($MN)
  • Table 13 Global Personalized Medicine Market Outlook, By Health Information Technology (2021-2030) ($MN)
  • Table 14 Global Personalized Medicine Market Outlook, By Telemedicine (2021-2030) ($MN)
  • Table 15 Global Personalized Medicine Market Outlook, By Personalized Nutrition & Wellness (2021-2030) ($MN)
  • Table 16 Global Personalized Medicine Market Outlook, By Complementary & Alternative Medicine (2021-2030) ($MN)
  • Table 17 Global Personalized Medicine Market Outlook, By Retail Nutrition (2021-2030) ($MN)
  • Table 18 Global Personalized Medicine Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 19 Global Personalized Medicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Personalized Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 21 Global Personalized Medicine Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 Global Personalized Medicine Market Outlook, By Antiviral (2021-2030) ($MN)
  • Table 23 Global Personalized Medicine Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 24 Global Personalized Medicine Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 25 Global Personalized Medicine Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 26 Global Personalized Medicine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Personalized Medicine Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Personalized Medicine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Personalized Medicine Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 30 Global Personalized Medicine Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 31 Global Personalized Medicine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.